


Amendments To The Claims:

1. (Previously presented) A compound of formula (I):



wherein A⁺ is the benzenesulphonate (besylate) anion;

R is H or C₁₋₆ alkyl; and

n is a number from 0.8 to 2.2.


2. (Previously presented) A compound of formula (I) according to claim 1 wherein R is H.

3. (Previously presented) A compound of formula (I) according to claim 1 wherein n is a number between 1.1 and 2.1.

4. (Previously presented) A compound of formula (I) according to claim 1 wherein n is about 2.

5. (Previously presented) A compound according to claim 1 which is 4-({[4-((2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl)methyl]amino}carbonyl]amino} methyl)benzamide benzenesulfonate dihydrate.

6. (Original) A process for the preparation of a compound of formula (I) as defined in claim 1, which process comprises the reaction of a compound of formula (IA);



with a source of the besylate anion and a suitable C₁₋₆alkanol and water.

7. (Previously presented) A compound of formula (I) as defined in claim 1 for use as a therapeutic agent in the treatment of patients with inflammatory conditions.

8. (Previously presented) A method of manufacture of a medicament comprising the step of incorporating a compound of formula (I) as defined in claim 1 in a pharmaceutical composition.

9. (Previously presented) A method for the treatment of a human or animal subject suffering from or susceptible to an inflammatory condition, which method comprises administering to said human or animal subject an effective amount of a compound of formula (I) as defined in claim 1.

10. (Original) A pharmaceutical composition, comprising a compound of formula (I) as defined in claim 1 optionally with one or more physiologically acceptable diluents or carriers.

11-13. (Cancelled)

14. (Previously presented) The method of treatment of claim 9, wherein the inflammatory condition is asthma.

15. (Previously presented) The method of treatment of claim 9, wherein the inflammatory condition is rhinitis.